Overview

Second Open Label Extension to Bridging Study CTBM100C2303

Status:
Completed
Trial end date:
2012-03-19
Target enrollment:
Participant gender:
Summary
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Tobramycin